Age-Stratified Risk of Carboplatin-Induced Nausea and Vomiting in Lung Cancer Patients.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
198 patients included in the analysis, 114 (57.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In multivariate analysis, age <70 years, no drinking history, and higher CBDCA dose were associated with non-CR. [CONCLUSION] Age <70 years, no drinking history, and higher CBDCA dose were identified as risk factors for CBDCA-induced nausea and vomiting.
[INTRODUCTION] Age has been reported as a risk factor for chemotherapy-induced nausea and vomiting.
- p-value p = 0.001
APA
Hashimoto K, Yokokawa T, et al. (2026). Age-Stratified Risk of Carboplatin-Induced Nausea and Vomiting in Lung Cancer Patients.. Oncology, 104(2), 125-136. https://doi.org/10.1159/000544875
MLA
Hashimoto K, et al.. "Age-Stratified Risk of Carboplatin-Induced Nausea and Vomiting in Lung Cancer Patients.." Oncology, vol. 104, no. 2, 2026, pp. 125-136.
PMID
40064150 ↗
Abstract 한글 요약
[INTRODUCTION] Age has been reported as a risk factor for chemotherapy-induced nausea and vomiting. However, few reports have described risk factors for nausea and vomiting with carboplatin (CBDCA). This study investigated whether the incidence of CBDCA-induced nausea and vomiting differs with age, using 70 years as the cutoff.
[METHODS] Patients who underwent CBDCA for lung cancer at the Cancer Institute Hospital of Japanese Foundation for Cancer Research between November 2020 and October 2023 were included in this retrospective study. The age cutoff was set at 70 years, with the complete response (CR; no vomiting/retching and no rescue medication) rate during the observation period as the endpoint.
[RESULTS] Of the 198 patients included in the analysis, 114 (57.6%) were ≥70 years old. The CR rate was 36.9% for patients <70 years old and 61.4% for patients ≥70 years old (p = 0.001). In univariate analyses, age <70 years, female sex, no drinking history, no smoking history, and higher CBDCA dose were associated with non-CR. In multivariate analysis, age <70 years, no drinking history, and higher CBDCA dose were associated with non-CR.
[CONCLUSION] Age <70 years, no drinking history, and higher CBDCA dose were identified as risk factors for CBDCA-induced nausea and vomiting.
[METHODS] Patients who underwent CBDCA for lung cancer at the Cancer Institute Hospital of Japanese Foundation for Cancer Research between November 2020 and October 2023 were included in this retrospective study. The age cutoff was set at 70 years, with the complete response (CR; no vomiting/retching and no rescue medication) rate during the observation period as the endpoint.
[RESULTS] Of the 198 patients included in the analysis, 114 (57.6%) were ≥70 years old. The CR rate was 36.9% for patients <70 years old and 61.4% for patients ≥70 years old (p = 0.001). In univariate analyses, age <70 years, female sex, no drinking history, no smoking history, and higher CBDCA dose were associated with non-CR. In multivariate analysis, age <70 years, no drinking history, and higher CBDCA dose were associated with non-CR.
[CONCLUSION] Age <70 years, no drinking history, and higher CBDCA dose were identified as risk factors for CBDCA-induced nausea and vomiting.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Diagnostic impact of tocilizumab on papillary thyroid cancer in a patient with systemic juvenile idiopathic arthritis.
- Real-world occurrence of severe gastrointestinal bleeding in patients receiving amivantamab plus lazertinib: A two-case series among 25 consecutive cases.
- Immunohistochemical Expression and Clinicopathological Assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 Expression in Desmoid Tumor.
- Metabolic tumor volume on F-fluorodeoxyglucose uptake as prognostic marker for osimertinib in patients with non-small cell lung cancer harboring sensitive EGFR mutation.
- Atezolizumab plus Bevacizumab with Transcatheter Arterial Chemoembolization (Sandwich Strategy) versus Atezolizumab plus Bevacizumab Alone in Hepatocellular Carcinoma: A Multicenter Retrospective Study.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.